PMEF
CGEM icon

Point72 Middle East FZE’s Cullinan Oncology CGEM Stock Holding History

Point72 Middle East FZE’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,195
Closed -$12.2K – 238
2023
Q4 		$12.2K Sell
1,195
-5,824
-83% -$51.6K ﹤0.01% 1389
2023
Q3 		$63.5K Buy
7,019
+1,549
+28% +$16.1K ﹤0.01% 1210
2023
Q2 		$58.9K Buy
+5,470
New +$58.1K ﹤0.01% 1274

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Point72 Middle East FZE's CGEM Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Cullinan Oncology (CGEM) in Q1 2024, closing a stake of 1,195 shares — an estimated $12.2K sold.

Point72 Middle East FZE first reported a position in CGEM in Q2 2023 and held it in 3 quarters. The position peaked at $63.5K in Q3 2023. 113 funds tracked by Wall St. Rank hold CGEM as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Cullinan Oncology position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,195 Cullinan Oncology shares in Q1 2024, an estimated $12.2K.
  • Point72 Middle East FZE first reported a position in Cullinan Oncology in Q2 2023 and held it in 3 quarters.
  • Point72 Middle East FZE's Cullinan Oncology position peaked at $63.5K in Q3 2023.
  • 113 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.